Fig. 2: LRRK2 kinase hyperactivity in vivo due to the presence of the LRRK2 p.Arg1067Gln (p.R1067Q) variant.
From: Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant
Monocyte lysates were analyzed by quantitative immunoblotting (a). Quantified immunoblotting data are presented as ratios of phospho-Rab10Thr73/total Rab10 and total Rab10/GAPDH (b), and phospho-LRRK2Ser935/total LRRK2 and total LRRK2/GAPDH (c), normalized to the average values obtained from the healthy control. The experiments were performed in duplicates, with each data point representing a technical replicate. LRRK2-dependent Rab10 phosphorylation (phospho-Rab10Thr73) as a readout for LRRK2 kinase activity was increased in the monocytes derived from the patient carrying the p.Arg1067Gln variant compared to the control.
